Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343532 · ClinicalTrials.gov registry record · Phase 1
SXC-2023 Cocaine Interaction Study
A Phase 1 study of Cocaine Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT06343532: Completed Phase 1 study of Cocaine Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
NCT06343532 is a Phase 1 study of Cocaine Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 17 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06343532, a Phase 1 study of Cocaine Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.
Primary Outcome
Assessing the number of treatment emergent adverse events using the most recent version of the Medical Dictionary of Regulatory Activities (MedDRA) preferred terms. Adverse events were either reported by the participants or determined by clinically significant abnormal findings on: i. Physical examination ii. Measurement of vital signs (heart rate, blood pressure) iii. Clinical laboratory findings
Conditions Studied
Interventions
- DRUG SXC-2023
- DRUG SXC-2023 Placebo
Study Locations (1)
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the finished NCT06343532 record still lists
NCT06343532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which SXC-2023 is the first listed.
NCT06343532 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06343532 about?
NCT06343532 is a clinical study titled "SXC-2023 Cocaine Interaction Study". The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.
What is the current status of trial NCT06343532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-11. Estimated completion is 2024-12-30.
What conditions does trial NCT06343532 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT06343532?
The interventions under investigation include: SXC-2023 (DRUG), SXC-2023 Placebo (DRUG).
Who is sponsoring clinical trial NCT06343532?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343532 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06343532's enrollment target sits among peer trials
17 25th of 26 higher than 2 of 26 other Cocaine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
COMPLETED · Phase 1
-
Cocaine Opioid Oxytocin Option - Limited
COMPLETED · Phase 1
-
The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)
COMPLETED · Phase 1
-
Phase1, STP7 Cocaine Drug-Drug Interaction Study
COMPLETED · Phase 1
-
Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
COMPLETED · Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI